06-15-05

Express Mail Label No.: EV 475171185 US

Die of Deposit: June 13, 2005

Docket No.: 18989-032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

LICANTS:

Bunn, et al.

SERIAL NUMBER:

10/772,076

EXAMINER:

Yong D. Pak

FILING DATE:

February 3, 2004

ART UNIT:

1652

For:

COMPOSITIONS AND METHODS OF TREATING DIABETES

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

- 1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (2 pages), in duplicate;
- 3. Copies of cited references B3; C4-21; and
- 4. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 18989-032. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ingrid A Beattie, Reg. No. 42,306

Cynthia A. Kozakiewicz, Reg. No.42,764

Attorneys for Applicants c/o MINTZ, LEVIN

Address all written correspondence to

Customer no.: 30623 Tel: (617) 542-6000

Date: June 13, 2005

TRA 2023021v1

Express Mail Label No.: EV 475171185 US

Opate of Deposit: June 13, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Bunn, et al.

SERIAL NUMBER:

10/772,076

EXAMINER:

Yong D. Pak

Attorney Docket No.: 18989-032

FILING DATE:

February 3, 2004

ART UNIT:

1652

FOR:

COMPOSITIONS AND METHODS OF TREATING DIABETES

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A3 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS:

Bunn et al.

U.S.S.N.:

10/772,076

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 19898-032.

Respectfully submitted,

Ingrid A Beattie, Reg. No. 42,306

Cynthia A. Kozakiewicz, Reg. No.42,764 Attorneys for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to

Customer no.: 30623 Tel: (617) 542-6000

Date: June 13, 2005

TRA 2023019v1

Express Mail No.: EV 475171185 US

Date of Deposit: June 13, 2005



Page 1 of 2 Attorney Docket No.: 18989-032

Please type a plus sign (+) in this box

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT						Application Number	10/772,076					
						Filing Date	ry 3, 2004					
						First Named Inventor	Bunn					
						Group Art Unit	1652					
(use as many sheets as necessary)						Examiner Name	Yong D. Pak 18989-032					
						Attorney Docket Number						
#X		2 7			U.S	PATENT DOCUMENTS						
Exam Initials	Cite No.	U.S. Patent Document No.		Issue Date 12/07/71	Name of Patentee(s) or Applicant(s) Higuchi		Class 128	Sub Class 260	Filing Date If Appropriate			
	*A1											
	*A2	4,789	,734	12/06/88	Pierschbacher		530	395				
	*A3	4,925,673		05/15/90	Steiner et al.		424	455				
Exam	Cite	lue	. Published	U.S. F Published		HED APPLICATION DOCUMENTS	Class	Cub				
Initials	No.		ication No.	Date	IVai	ne of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate			
					FOREI	GN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number			Name o	of Patentee(s) or Applicant(s)	Date of Transla Publication Yes		Translation Yes No			
	В3	WO 89/07136			WHITEHEAD INSTITUTE FOR BIOCHEMICAL RESEARCH;		08/10/89					
	<u> </u>				HOWA	RD HUCHES MEDICAL INSTITUTE	<u> </u>					
y - 1, - 1		<u> </u>	L	uen naon	ADE							
Exam	Cite	ja –	<u>U</u> I	HER PRIOR	AHIT	NON PATENT LITERATURE DOCUM	ENIS					
Initials	No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.										
	C4	GENBANK Accession No. AF169803 (2000)										
	C5	GENBANK Accession No. AAF04812 (2000)										
	C6	GENBANK Accession No. XM229210										
	C7	GENBANK Accession No. XP229210										
	C8	GENBANK Accession No. P56395 (2004)										
	C9	GENBANK Accession No. P00173 (2004)										
	C10	GENBANK Accession No. P20070 (2005)										
	C11	GENBANK Accession No. AL034347 (2005)										
	C12	Gregoriadis Drug Carriers Biol. Med., pp. 287-341 (Academic Press) (1979)										
	C13	Johns	son et al. J	. Biol. Chen	n., 273(52):35147-35152 (1998)						
	C14	Kotar	ni et al. <i>Ana</i>	al. Biochem.	, 284(1):65-69 (2000)						
	C15	Kotin	et al. Proc	. Natl. Acad	l. Sci. U	<i>ISA</i> , 87:2211-2215 (1990)						
	C16	Leiter et al. Am. J. Pathol., 128(2):380-383 (1987)										

Express Mail No.: EV 475171185 US

Page 2 of 2

Date of Deposit: June 13, 2005

Attorney Docket No.: 18989-032

C18	Morsy et al. J. Cell. Biochem., Suppl. 17E, pp. 226, Abstract SZ109 (1993)	
C19	Rosenberg et al. N. Engl. J. Med., 323(9):570-578 (1990)	
C20	Waddington et al. Anal. Biochem., 292(2):234-244 (2001)	
C21	Zhu et al. Proc. Natl. Acad. Sci. USA, 96(26):14742-14747 (1999)	

^{*} By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A3 are not submitted.

Examiner Signature	Date Considered	
-----------------------	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 1983916v1